Eli Lilly and Company (NYSE:LLY – Get Free Report)’s stock price was up 0.1% on Monday after Citigroup raised their price target on the stock from $1,060.00 to $1,250.00. Citigroup currently has a buy rating on the stock. Eli Lilly and Company traded as high as $895.88 and last traded at $893.64. Approximately 576,701 shares traded hands during trading, a decline of 80% from the average daily volume of 2,947,208 shares. The stock had previously closed at $892.70.
A number of other equities analysts also recently weighed in on the stock. Berenberg Bank lifted their target price on shares of Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a research note on Wednesday, August 14th. Guggenheim lifted their price objective on Eli Lilly and Company from $884.00 to $1,030.00 and gave the stock a “buy” rating in a research report on Friday, August 16th. Truist Financial boosted their price objective on Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the company a “buy” rating in a research note on Thursday, October 10th. Evercore ISI upgraded Eli Lilly and Company to a “hold” rating in a report on Thursday, September 5th. Finally, Wells Fargo & Company increased their price target on Eli Lilly and Company from $875.00 to $1,000.00 and gave the stock an “overweight” rating in a report on Friday, August 9th. Three investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $1,013.41.
Check Out Our Latest Stock Analysis on Eli Lilly and Company
Institutional Inflows and Outflows
Eli Lilly and Company Stock Up 0.0 %
The company has a current ratio of 1.11, a quick ratio of 0.87 and a debt-to-equity ratio of 1.74. The stock has a market cap of $848.59 billion, a P/E ratio of 131.61, a price-to-earnings-growth ratio of 3.24 and a beta of 0.42. The stock’s fifty day moving average price is $919.74 and its 200 day moving average price is $863.20.
Eli Lilly and Company (NYSE:LLY – Get Free Report) last released its earnings results on Thursday, August 8th. The company reported $3.92 EPS for the quarter, beating analysts’ consensus estimates of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The business had revenue of $11.30 billion for the quarter, compared to analysts’ expectations of $9.83 billion. As a group, research analysts forecast that Eli Lilly and Company will post 14.05 earnings per share for the current fiscal year.
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Featured Stories
- Five stocks we like better than Eli Lilly and Company
- What is the Nasdaq? Complete Overview with History
- 3 Oil Stocks to Watch Before Earnings Come Out
- Earnings Per Share Calculator: How to Calculate EPS
- Is American Express Stock’s Sell-the-News Reaction a Buying Opp?
- 3 REITs to Buy and Hold for the Long Term
- Alphabet’s Earnings Could Surprise—Should You Buy Now?
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.